Llombart-Cussac, A., Fernandez-Murga, L., Martinez, E., Santaballa, A., Bermejo, B., Rodriguez-Lescure, A., Iranzo, V., Morena, P. D. L., Iranzo-Barreira, J., Cortés, J., Riva, F., García, J. M. P., Dustin, D., Vidal-Martinez, J., Liébana, S. M., Serrano-Garcia, L., Cejalvo, J. M. (2025). Circulating tumor DNA (ctDNA)-based minimal residual disease (MRD) measured by Guardant Reveal in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) with long-term disease control on first-line trastuzumab-pertuzumab.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.1052